CAS: 7059-24-7; Chromomycin A3

📜Nickel Titanate 在 C体系中,用 Melt作为反应溶剂,获得 [(2S,3R,4S)-6-[[(6S,7S)-6-[(4R,5R,6R)-4-[(4S,5S,6S)-4-[(4S,5S,6S)-5-Acetyloxy-4-Hydroxy-4,6-Dimethyloxan-2-Yl]Oxy-5-Hydroxy-6-Methyloxan-2-Yl]Oxy-5-Hydroxy-6-Methyloxan-2-Yl]Oxy-7-[(1R,3S,4S)-3,4-Dihydroxy-1-Methoxy-2-Oxopentyl]-4,10-Dihydroxy-3-Methyl-5-Oxo-7,8-Dihydro-6H-Anthracen-2-Yl]Oxy]-4-[(4S,5S,6S)-4-Hydroxy-5-Methoxy-6-Methyloxan-2-Yl]Oxy-2-Methyloxan-3-Yl] Acetate,Nickel Titanium
参考文献:通过 Ffc 剑桥工艺生产镍钛:工艺参数的细化
标题:通过 Ffc 剑桥工艺生产镍钛:工艺参数的细化
摘要:电化学 Ffc 剑桥工艺非常适合 Niti 生产,因为它避免了与传统制造路线相关的 Ni 偏析.通过混合金属氧化物在熔融 Cacl2 盐浴中的直接电脱氧,可以生产均匀的低氧产品.这项工作建立在先前有关还原 Niti 的文献的基础上 [J. 电化学.S°C.,155,E171 (2008); 下巴.科学.Bull.,51,2535 (2006)] 通过调查还原温度和构造材料对形成的相的影响.先前的工作表明,使用 Ti 阴极集电器可以使 Ti 富集,在环境温度下形成单斜 B19(') 单斜 Niti [J. 电化学.S°C.,155,E171 (2008)].使用 Ni 集电器导致产品中 Ni 富集,在环境温度下稳定高温 B2 立方形式.从 1173 到 1273 K 进行的所有还原都是如此,但对于 1123 K 及以下,形成了单斜晶 B19(') Niti.Niti 集电器在环境温度下产生
Doi:10.1149/1.3289996

专利信息

专利号:US-10925977-B2
优先权日:2006-10-05
标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
发明人：YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

专利号:US-5084378-A
优先权日:1987-11-30
标题:Enhanced detection of fluorescence quenching in labeled cells
发明人：CRISSMAN HARRY A; STEINKAMP JOHN A
权利人:US ENERGY
摘要:A method is provided for quantifying BrdU labeled DNA in cells. The BrdU is incorporated into the DNA and the DNA is stained with a first fluorochrome having a fluorescence which is quenchable by BrdU. The first fluorochrome is preferably a thymidine base halogen analogue, such as a Hoechst fluorochrome. The DNA is then stained with a second fluorochrome having a fluorescence that is substantially uneffected by BrdU. The second fluorochrome may be selected from the group consisting of mithramycin, chromomycin A3, olivomycin, propidium iodide and ethidium bromine. The fluorescence from the first and second fluorochromes is then measured to obtain first and second output signals, respectively. The first output signal is substracted from the second output signal to obtain a difference signal which is functionally related to the quantity of BrdU incorporated into DNA. The technique is particularly useful for quantifying the synthesis of DNA during the S-phase of the cell cycle.

专利号:US-7153691-B2
优先权日:2002-11-13
标 题 :Method of identifying and assessing DNA euchromatin in biological cells for detecting disease, monitoring wellness, assessing bio-activity, and screening pharmacological agents
发明人：FERGUSON GARY WILLIAM
权利人:G6 SCIENCE CORP
摘要:The present invention is a method of identifying and assessing DNA euchromatin in biological cells. The amount and/or distribution of DNA euchromatin generally relates to RNA/protein synthesis, which may change in certain conditions, such as disease, and/or cellular response to environmental and/or chemical agents. The present invention detects the potential presence of disease by assessing DNA euchromatin in ostensibly normal cells and similarly provides means to monitor and assess treatment response. The present invention may also be used to assess how application (or removal) of influences, such as environment, radiation, chemical agents, medications, herbs, vitamins, etc., interact to effect cells, establishing uses in monitoring wellness and pharmacological screening. Additional uses include assessing age related disorders, allergies, infections, Alzheimer's disease, ‘Time of Death’, chronic fatigue syndrome, etc. The method may be advantageously applied to biological cells including micro-organisms, plants, animals, or cultured cells, alone or in conjunction with other markers.

专利号:US-12054512-B2
优先权日:2017-11-10
标 题 :Sting modulator compounds, and methods of making and using
发明人：VYSKOCIL STEPAN; CIAVARRI JEFFREY; CULLIS COURTNEY; ENGLAND DYLAN BRADLEY; GOULD ALEXANDRA E; GREENSPAN PAUL; HU YONGBO; LANGSTON STEVEN; LI GANG; MIZUTANI HIROTAKE; OKANIWA MASANORI
权利人:TAKEDA PHARMACEUTICALS CO
摘要:The present disclosure provides STING modulators/agonists, and methods of synthesis and methods for using for the prophylaxis or treatment of cancer and other STING-related diseases.The present disclosure relates to a compound represented by the Formula (I):wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.

专利号:US-9803240-B2
优先权日:2008-04-01
标题 :Stabilized nucleic acid dark quencher-fluorophore probes
发明人：COOK RONALD M; LYTTLE MATT
权利人:BIOSEARCH TECH INC
摘要:The present invention provides a new class of solids supports for synthesis of modified oligomers of nucleic acids, and nucleic acid probes that have a format expediently synthesized on the new supports. Exemplary solid supports include at least one quencher bound through a linker to the solid support. Various exemplary embodiments include a moiety that stabilizes a duplex, triplex or higher order aggregation (e.g., hybridization) of nucleic acids of which the oligomer of the invention is a component. Other components of the solid support include moieties that stabilize aggregations of nucleic acids, e.g., intercalators, minor groove binding moieties, bases modified with a stabilizing moiety (e.g., alkynyl moieties, and fluoroalkyl moieties), and conformational stabilizing moieties, such as those described in commonly owned U.S. Patent Application Publication No. 2007/0059752.

专利号:KR-101513003-B1
优先权日:2006-10-05
标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy compositions and applications